Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Nektar Therapeutics Stock Gained 13.6% in June

By Maxx Chatsko - Jul 8, 2019 at 6:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Was last month a turning point in a not-so-good year for shareholders?

What happened

Shares of Nektar Therapeutics (NKTR -0.77%) rose more than 13% last month, according to data provided by S&P Global Market Intelligence. The company announced promising results at the American Society of Clinical Oncology (ASCO) annual meeting for a combination therapy involving NKTR-214 and Opdivo from Bristol-Myers Squibb in advanced melanoma.

At the 12.7-month median follow-up, the combination achieved an objective response rate (a reduction in tumor size) of 53% and a complete response rate (no detectable signs of disease) of 34%. That means 13 of the 20 patients who saw an objective response achieved a complete response. The data were from a phase 2 clinical trial, and the phase 3 clinical trial for the combination therapy is now recruiting patients. 

An arrow on a springboard representing the last and tallest column in a chart.

Image source: Getty Images.

So what

The numbers from the midstage trial are impressive. Opdivo alone triggered a complete response in 18% of patients in a four-year study. Meanwhile, a combination of Opdivo and Yervoy achieved a complete response in 21% of patients. 

The NKTR-214 and Opdivo combination has only been evaluated for about one year, but analysts are optimistic it can keep up the promising responses, especially considering the complete response has improved over time and that 80% of patients who responded to treatment maintained that response at the 12.7-month milestone. 

Now what

Nektar is now valued at $6 billion, a far cry from the nearly $18 billion market cap it sported in early 2018. The company has lost $2 billion, or 25%, of its market valuation since its February peak. Will a promising showing at ASCO help to turn things around? It certainly can't hurt. NKTR-214 is being evaluated in two late-stage trials, two midstage trials, and three early stage trials -- mostly in combination with other drugs. That makes it the company's most important asset, which means ongoing success could solidify Nektar's future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
NKTR
$3.88 (-0.77%) $0.03
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$76.19 (0.30%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.